(MedPage Today) — The FDA expanded the indication for semaglutide (Wegovy) to treating adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), the agency announced.
The glucagon-like peptide-1 (GLP-1) receptor agonist…
Source link : https://www.medpagetoday.com/gastroenterology/generalhepatology/117043
Author :
Publish date : 2025-08-18 18:20:00
Copyright for syndicated content belongs to the linked Source.
